第三线免疫疗法后的第四阶段胃癌的转化手术:一个病例报告
Sevindzh F Evdokimova1, Anna L Kornietskaya1, Larisa V Bolotina1
1P. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, Russia.
Frontiers in oncology
|December 23, 2024
概括
第四期胃癌的生存率很差. 在第三线 pembrolizumab 免疫疗法后的转化手术导致了一名患者的22个月无复发生存,这表明了潜在的益处.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 免疫治疗是一种免疫疗法.
背景情况:
- 第四期胃癌的预后很糟糕,五年生存率低于10%.
- 系统疗法对晚期胃癌提供有限的长期益处.
- 化疗后的转换手术表明,在某些具有持久反应的患者中,生存率有所改善.
研究的目的:
- 报告一例临床转换手术的病例,该病例发生在患有第四期胃癌的患者身上,该患者接受了第三线 pembrolizumab 治疗.
- 评估在晚期胃癌中免疫治疗后的转化手术的疗效.
主要方法:
- 一名患有第四期胃癌的患者接受了第三线 pembrolizumab.
- 患者获得了持久的临床反应,随后接受了转换手术.
- 监测了手术后的结果,包括没有复发的生存率.
主要成果:
- 患者对 pembrolizumab.com 产生了持久的临床反应.
- 在免疫治疗后成功进行了转换手术.
- 患者在手术干预后22个月内没有复发.
结论:
- 在第三线 pembrolizumab 之后的转化手术可能是选择第四期胃癌患者的可行选择.
- 这种方法可能会导致长时间的无复发生存.
- 需要进一步研究免疫疗法引导的转换手术,以治疗晚期胃癌.
相关概念视频
01:27Tumor Immunotherapy
475
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
475
01:25Peptic Ulcer Disease V: Surgical Management and Nursing Care
228
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
Surgical Interventions for Peptic Ulcer Disease
228